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Background: The femoropopliteal vein (FPV) has been used successfully for vascular reconstructions at multiple sites. To
date, there have been no studies documenting patency of the FPV graft in the femorofemoral position. Our goal was to
assess long-term patency of the FPV graft used for femorofemoral bypass (FFBP).
Methods: Patients undergoing FFBP over a 10-year period were studied. Those in whom the FPV was used as a conduit
were analyzed for runoff resistance score to assess how patients with poor runoff fared. Poor runoffwas defined as a runoff
resistance score of >7 (1  normal runoff, 10  total occlusion of all runoff vessels).
Results: Fifty-four patients underwent FPV FFBP as a sole procedure (n  16, 30%) or as a portion of an aortofemoral
reconstruction with a FFBP component (n  38, 70%). Mean ( SD) follow-up was 47  33 months. The 1-, 3-, and
5-year primary patencies were 97%, 93%, and 76%. The 5-year assisted primary and secondary patency rates were 85% and
90%. Among 27 patients with poor runoff (runoff resistance score of>7), the cumulative 40 month patency rate was 90%.
Among patients in whom FPV FFBP was performed as a primary procedure (no aortofemoral component), there were no
graft failures.
Conclusions: FFBP performed with FPV has excellent 1-, 3, and 5-year patency rates. FPV has sustained patency for FFBP
in patients with poor runoff. ( J Vasc Surg 2005;42:35-9.)The role of femorofemoral bypass (FFBP) has changed.
When first described by Vetto in 1962,1 FFBP was in-
tended for use in debilitated patients with unilateral iliac
occlusive disease who were too ill to undergo an aortic-
based procedure. Contemporary FFBP is often used to
treat complex vascular problems associated with failed aor-
toiliac/femoral bypasses or failed endovascular therapies.
This bypass, although ideal for high-risk patients, has been
characterized by patency rates inferior to in-line reconstruc-
tive techniques.2,3
The femoral popliteal vein (FPV) graft has been used
successfully as a conduit in many vascular beds.4-12 In
1997, we reported 5-year primary and assisted primary
patency rates of 84% and 100%, respectively, for aortoiliac/
femoral reconstructions with FPV grafts in the treatment of
infected aortic prostheses.4 Almost half of these reconstruc-
tions involved a unilateral aortofemoral bypass coupled
with a FFBP, both fashioned from FPV grafts. Because of
the favorable experience with the FFBP in these patients,
we expanded the use of FPV grafts for FFBPs.
In this report, we review our entire experience with
FPV grafts for FFBPs, with a focus on durability. Because
runoff is a major determinant of patency in these recon-
structions, we performed a separate analysis of patients with
FPV grafts who had compromised runoff.
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The records of all patients who underwent a FFBP over
a 10-year period in a single university-based practice were
examined. These cases were indexed from an institutional
computerized registry of operative cases. Study data were
obtained from inpatient and outpatient treatment records.
The data from all patients with FPV grafts were entered into
a registry that included operative details, course, and out-
comes as well as a prospective follow-up program.
The follow-up consisted of a return visit within 1
month after discharge, at 3-month intervals for the first
postoperative year, and at 6-month intervals thereafter.
Follow-up was conducted with clinical examination, non-
invasive vascular studies, and duplex ultrasound examina-
tion.
Duplex findings suggesting a hemodynamically signif-
icant stenosis consisted of a focal increase in peak systolic
flow velocity that, when indexed against the peak systolic
flow velocity in adjacent proximal or distal segments,
yielded a ratio of 3.0. These findings, as well as a return of
symptoms or a significant change in ankle systolic pressures,
prompted further evaluation with computed tomographic
or conventional arteriography.
Patients underwent preoperative duplex vein mapping
to assess patency, diameter, and available length of FPV.
The FPV was considered adequate for use if it was 6 mm
in diameter and had no significant evidence of previous
deep venous thrombosis.
The technique of FPV harvest has been described in
detail elsewhere.13,14 Briefly, the vein is exposed in the
subsartorial canal through an incision over the lateral bor-
der of the sartorius muscle. After ligation of side branches,
the vein is left in situ until a measurement of required
length can be performed. The common femoral artery is
also exposed through this lateral incision.
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the vein is harvested taking care to divide the proximal vein
flush with the junction of the profunda femoris and com-
mon femoral veins so that no stump is left as a source for
thrombus formation. The vein is flushed thoroughly,
everted, and the valves excised. The FFBP tunnel is created
in the subcutaneous tissues of the lower abdomen. Anasto-
moses are performed in standard end-to-side fashion.
Demographic data, comorbidities, indication for oper-
ation, and patency rates were examined for both groups.
The runoff resistant scores15 were calculated to examine
patency rates in patients with poor runoff. According to this
system, a minimum value of 1 indicates excellent runoff
with no distal disease, and a maximum value of 10 denotes
no runoff (blind vascular segment).15 Poor runoff in this
report is defined as a runoff resistance score of7. Patency
was also examined in another subgroup of patients who had
FPV FFBP as a primary operation (no concomitant aortic
inflow procedure). Primary patency was defined according
to Society for Vascular Surgery recommended reporting
standards.15 Patency rates and limb salvage were described
using the Kaplan-Meier survival method.
RESULTS
During the study period, 54 patients underwent FPV
FFBP: 38 (70%) had an aortobifemoral bypass performed
with two FPV grafts, an aortofemoral segment, and a FFBP
segment; 16 (30%) had FPV FFBP as a solitary procedure.
The demographic, comorbidity data, and the operative
indications are shown in Table I. Most (n  38) of these
procedures were done for either graft infection or throm-
bosis of a previously placed prosthetic graft, and 36 (95%)
of these 38 patients had occlusive disease. All patients who
had FFBP as a sole procedure (n  16) had occlusive
disease. The mean follow-up time was 47  33 months
among surviving patients. Follow-up was complete in 49
patients (91%); the remaining five patients either died or
were lost to follow-up.
Primary patency rates at 1, 3 and 5 years for patients
undergoing FPV FFBP were 97%, 93%, and 76% (Fig).
Assisted primary patency and secondary patency rates at 1,
3, and 5 years were 100%, 91%, and 85% and 100%, 95%,
and 90%, respectively (Fig).
None of the 16 patients who had FPV FFBP only
(without concomitant aortic inflow procedure) required
graft revision or had thrombosis of the graft. The primary
patency for this group was 100%, with a mean follow-up of
36  29 months.
There were five failures, and all were patients who had
complete aortofemoral reconstructions performed because
of aortic graft infection. Three patients had asymptomatic
graft stenoses detected on routine duplex surveillance, two
of whom underwent surgical revision with vein patch an-
gioplasty at 7 and 12 months after operation. The third
patient had stenting of a stenotic area in the FFBP 36
months after operation. All three grafts remain open. A
fourth patient had FFBP thrombosis at 25 months after
operation and required thrombectomy and distal anasto-motic revision. This graft also has remained open since
revision. A fifth patient had graft thrombosis at 43 months
after operation and required amputation for nonreversible
lower extremity ischemia.
Information was available to calculate runoff resistance
scores in 49 of the 54 patients who had FPV FFBP. Of
these, 26 patients (53%) had scores of7 and were consid-
ered to have poor runoff. Nine of these 26 patients had
Fig. Kaplan-Meier analysis showing primary, primary assisted, and
secondary patency for femoropopliteal vein femorofemoral bypass.
Table I. Demographics, comorbidities, and operative
indications
Demographics
Number of patients 54
Female gender 25 (46%)
Median age 60
Comorbidities
HTN 44 (81%)
CAD 23 (43%)
DM 14 (26%)
COPD 2 (4%)
ESRD 2 (4%)
CRI 2 (4%)
Hyperlipidemia 21 (39%)
Tobacco use 38 (70%)
Operative indications
Graft infection 38 (70%)
Lower extremity ischemia 9 (17%)
Lower extremity ischemia
secondary to graft occlusion 11 (20%)
HTN, Hypertension; CAD, coronary artery disease; DM, diabetes mellitus;
COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal
disease; CRI, chronic renal insufficiency.concomitant lower extremity bypasses at the time of FFBP.
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poor runoff were 100% and 90%, respectively. Beyond 40
months, the Kaplan-Meier survival curve was unreliable,
with the standard error 10%.
Sixteen (30%) of the 54 patients who had FPV FFBP
had postoperative morbidity. Nine patients had postoper-
ative wound problems at vein harvest sites (5 wound dehis-
cences and 4 wound infections requiring antibiotic ther-
apy). Additional morbidity included two cases of renal
failure, two cases of pancreatitis, one myocardial infarction,
and a single episode each of peritonitis and Clostridium
difficile colitis. Almost all morbidity occurred in patients
being treated for aortic graft infection. There were three
deaths, all in patients who required treatment for aortic
graft infection. The 30-day mortality was 5.5%.
There was no long-term venous morbidity from vein
harvest, including symptoms of venous claudication or
venous stasis ulceration. There was short-term venous mor-
bidity, primarily manifested by the requirement for fas-
ciotomy. Of 78 limbs that had FPVs harvested, 27 (35%)
underwent fasciotomy. This was assessed clinically at the
time of the initial procedure, and fasciotomywas performed
concurrently. All but one of the fasciotomies was per-
formed in patients undergoing FFBP as part of the opera-
tive treatment of an aortic graft infection. There were 16
limbs at risk in patients who underwent FPV FFBP as a sole
procedure, and one fasciotomy (6%) was performed in this
group. The patient who required fasciotomy had concom-
itant harvest of the ipsilateral greater saphenous vein.
DISCUSSION
This study shows that FFBP with FPV is a durable
procedure with 5-year primary, assisted primary, and sec-
ondary patency rates of 76%, 85%, and 90%, respectively.
Excellent patency was achieved in a high-risk population of
patients, many of whom had active graft infection, failure or
thrombosis of vascular grafts, and poor runoff. There is one
other report describing outcomes of FPV FFBP. Me-
neghetti et al16 reported 20 of these reconstructions in
Table II. Published 5-year primary, assisted primary, seco
femorofemoral bypass with varying conduit types.
Conduit type Study
No. of
patients
Prosthetic Plecha (1984)17 119 
Lamerton (1985)18 54 
Criado (1993)19 110 
Schneider (1994)3 91 
Mingoli (2000)20 228 
Aortouniiliac stent graft Hinchcliffe (2003)21 231 
Lipsitz (2003)22 110 
Greater saphenous vein Hakaim (1994)23 25 
Jicha (1995)24 34 
Femoropopliteal vein Current study (2004) 54
NR, Not reported.selected patients with either prosthetic graft infection orpoor runoff. With a mean follow-up of 24 months, the
authors concluded that the FFBP was an effective conduit
in these disadvantaged patients, although formal patency
rates were not reported.
There is a large body of literature that examines out-
comes of prosthetic FFBP (Table II). Reported 3- to 5-year
patency rates range from 60% to 72% when FFBP is done
for occlusive disease. Patients who have undergone previ-
ous aortofemoral bypass and who require FFBP for unilat-
eral limb occlusion have worse patency than those who
undergo prosthetic FFBP as a primary procedure.25-27 In
addition, patients with poor runoff fare worse than those
with good runoff.28 Patients who undergo FFBP as part of
an aortouniiliac stent graft procedure have higher FFBP
patency rates that range from 83% to 95% at 5
years21,22,29,30 (Table II). This is most likely reflective of
good runoff in patients with aneurysmal disease.
There are fewer reports of patients undergoing FFBP
with greater saphenous vein (Table II).23,24 It is interesting
to note that patency rates with this autogenous conduit
appear inferior to those of prosthetic FFBP. This mirrors
our own disappointing experience with greater saphenous
vein reconstructions following removal of infected aortic
prostheses.4 We noted that the smaller greater saphenous
vein grafts were subject to kinking and distortion as well as
were more likely to be compromised by small amounts of
intimal hyperplasia compared with large caliber FPV
grafts.4
Excellent patency (90% at 40 months) in patients with
FPV FFBP was realized in patients with poor runoff as
determined by calculated runoff resistance scores. In addi-
tion, the subgroup of patients who had FPV FFBP as a
primary procedure had 100% primary patency at 5 years.
These values are the highest reported patency rates to date
for FFBP in patients with occlusive disease and exceed
those reported for prosthetic FFBP (Table II).
Another advantage of the FPV FFBP is the low infec-
tion rate. There were no cases of FPV graft infection in this
series despite the large number of patients who underwent
y patency, and graft infection rates (when reported) of
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highest for vascular prostheses at any location.
The disadvantages of using the FPV for FFBP include
the additional operative time for harvest, the potential for
compartment syndrome, and the need for fasciotomy.
Long-term venous morbidity is rare31 and was not seen in
this series. Almost all cases of fasciotomy in patients under-
going FPV FFBP were in those with infected aortic pros-
theses who had concomitant FPV aortofemoral bypass with
recognized risk factors for compartment syndrome, includ-
ing severe pre-existing lower extremity ischemia, prolonged
aortic cross-clamp time, and massive crystalloid require-
ments.32 The only patient undergoing FPV FFBP as a
primary procedure who required fasciotomy had concom-
itant harvest of the ipsilateral greater saphenous vein, an-
other recognized risk factor for compartment syndrome.32
In conclusion, we believe that we have shown that
FFBP with FPV is a durable procedure and that the FPV
may be the best conduit for this operation in patients with
extensive occlusive disease. That is not to say that prosthetic
FFBP does not have a role. It will continue to be useful in
patients with favorable anatomy and runoff, such as those
with aneurysmal disease, particularly those undergoing aor-
touniiliac stent graft placement.21,22,29,30 However, in pa-
tients with occlusive disease and poor runoff as well as in
complex patients with graft infections or failure of previous
interventions, FPV FFBP is a durable procedure.
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Dr Thomas Naslund (Nashville, TN). The authors have
provided a summary of their experience with the use of femoral-
popliteal vein as a femorofemoral bypass conduit. Their experience
with this conduit is unparalleled, and their continued publication
of its use over the last decade is commendable. An important
avenue of therapy has been tapped by evaluating the use of the
femoral-popliteal vein graft for isolated femorofemoral bypass. The
authors have demonstrated a patency superior to their own expe-
rience with synthetic grafts and provide a contribution to the
literature by establishing this technique for consideration by all.
Although their data show patency benefit, we must be reminded
that this benefit was realized by comparing vein with a 40% 5-year
patency of synthetic femorofemoral bypass grafts.
I would like to ask three questions:
First, do you currently utilize femoral-popliteal vein as the
choice conduit for femorofemoral bypass in your institution? In
answering that question, I would like for you to comment on your
indication for use of synthetic bypass grafts.
Second, do you consider patients with previous saphenous
vein harvest candidates for femoral-popliteal vein grafts for routine
femorofemoral bypass, and should such patients undergo prophy-
lactic fasciotomy at the time of procedure?
And finally, what increase in operative time is anticipated in
the use of femoral-popliteal vein as opposed to synthetic graft for
femorofemoral bypass?
I appreciate the opportunity to make comment on this fine
paper and thank the Association for the opportunity to do so.
Dr Victor D’Addio. Response to question 1. We preferen-
tially use femoral-popliteal vein (FPV) for femorofemoral bypass
(FFBP) in patients who have thrombosed previously placed aorto-
femoral or femorofemoral prosthetic grafts, have a graft infection
involving the groins, or have a remote site of infection. In addition,
we use the FPV in patients with compromised runoff. As an
institution, we have become very comfortable with use of FPV in
multiple vascular beds, and based on our positive experience withthis specific conduit, we do use it primarily in some patients.
Prosthetic FFBP clearly still has a role in patients who require this
extra-anatomic reconstruction. It is best used for patients with
favorable runoff, such as patients who have aneurysmal disease and
require FFBP after aortouniiliac stent grafting.
Response to question 2. Patients who have had previous
greater saphenous vein (GSV) harvest continue to be candidates
for harvest of the ipsilateral FPV, so we do not consider previous
GSV harvest a contraindication to harvest of the FPV. As our data
show, the risk of fasciotomy is low in patients undergoing FFBP as
a sole procedure. Only one patient who underwent FFBPwith FPV
as a sole procedure required fasciotomy, and this patient under-
went concomitant GSV harvest. Concomitant harvest of the GSV
is indeed a risk factor for the requirement of fasciotomy, as previ-
ously published by Modrall et al.32
The other major factor that affects the need for fasciotomy is
the degree of lower extremity ischemia preoperatively. Patients
with an ankle-brachial index (ABI) of 0.4 were found to require
fasciotomy significantly more often than those patients with higher
ABIs. Other factors that may affect the need for fasciotomy are
length of vein harvested, volume of intraoperative fluid, and dura-
tion of operative ischemia.
We do not perform prophylactic fasciotomy. The decision to
perform a fasciotomy is based on intraoperative physical assessment
of the lower extremity after revascularization along with consider-
ation of the previously mentioned factors.
Response to question 3. There is an increase in operative
time when the FPV is used as a conduit. Harvest and preparation of
the vein take approximately 2 hours. The specific technique of
harvest is given in the article. The valves in the vein are directly
lysed after everting the vein, and this requires time in addition to
the actual harvest time. We have found that because of the large
caliber of the vein, use of a valvulotome is inadequate for valve lysis
and have gone to direct valve lysis. This takes a bit longer but
prevents stenoses at inadequately lysed valve sites.
